Earnings History Data for Alnylam Pharmaceuticals, Inc. (ALNY) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
02-11-2023	PM		ALNY	Alnylam Pharmaceuticals, Inc.	18,980	1.15	-1.61	-3.32	Alnylam Pharmaceuticals beats Q3 top and bottom line estimates; updates FY23 outlook [11/2/2023 8:05 AM]	161.53	4.53 (2.89%)	161.53	0.0 (0.00%)	148.10 - 242.97	745,236	630,000	17,609
Alnylam Pharmaceuticals Q3 2023 Earnings Preview [11/1/2023 1:10 PM] Alnylam Pharmaceuticals beats Q3 top and bottom line estimates; updates FY23 outlook [11/2/2023 8:05 AM]
03-08-2023	PM		ALNY	Alnylam Pharmaceuticals, Inc.	23,540	-2.21	-1.72	-2.29	Alnylam Pharmaceuticals Non-GAAP EPS of -$1.62 misses by $0.28, revenue of $318.75M misses by $31.82M [8/3/2023 8:29 AM]	190.04	3.03 (1.62%)	0.0	0.0 (0.00%)	179.19 - 242.97	529,853	540,000	0
Alnylam Pharmaceuticals Q2 2023 Earnings Preview [8/2/2023 1:41 PM] Alnylam Pharmaceuticals Non-GAAP EPS of -$1.62 misses by $0.28, revenue of $318.75M misses by $31.82M [8/3/2023 8:29 AM]
04-05-2023	PM	8:00 AM ET (May 4)	ALNY	Alnylam Pharmaceuticals, Inc.	24,720	-1.40	-1.97	2.00	Alnylam Pharmaceuticals Non-GAAP EPS of -$1.06 beats by $0.37, revenue of $319.29M beats by $6.76M [5/4/2023 8:04 AM]	205.39	5.89 (2.95%)	0.0	0.0 (0.00%)	117.58 - 242.97	543,452	770,000	0
Alnylam Pharmaceuticals Q1 2023 Earnings Preview [5/3/2023 1:37 PM] Alnylam Pharmaceuticals Non-GAAP EPS of -$1.06 beats by $0.37, revenue of $319.29M beats by $6.76M [5/4/2023 8:04 AM]
23-02-2023	PM	8:00 AM ET (Feb 23)	ALNY	Alnylam Pharmaceuticals, Inc.	27,410	-1.68	-2.13	-2.16	Alnylam Pharmaceuticals Non-GAAP EPS of -$1.39 beats by $0.09, revenue of $335.03M beats by $22.58M [2/23/2023 8:01 AM]	195.67	-5.43 (-2.70%)	201.10	0.0 (0.00%)	117.58 - 242.97	1,259,994	640,000	7,431
Alnylam Pharmaceuticals Non-GAAP EPS of -$1.39 beats by $0.09, revenue of $335.03M beats by $22.58M [2/23/2023 8:01 AM] Alnylam off 4% despite earnings beats on disappointing 2023 product revenue outlook [2/23/2023 2:32 PM]
27-10-2022	PM	8:00 AM ET (Oct 27)	ALNY	Alnylam Pharmaceuticals, Inc.	23,830	-3.32	-1.84	-1.72	Alnylam Pharmaceuticals reports Q3 earnings miss; reaffirms FY22 guidance [10/27/2022 8:07 AM]	193.17	-7.85 (-3.91%)	198.00	-3.02 (-1.50%)	117.58 - 236.80	1,484,619	950,000	8,727
Alnylam Pharmaceuticals reports Q3 earnings miss; reaffirms FY22 guidance [10/27/2022 8:07 AM] Alnylam halts study for rare disease therapy citing U.S. drug pricing reforms [10/27/2022 12:15 PM] Drug/Biotech Stocks' Q3 Earnings on Oct 27: MRK, GILD & More [Oct-26-22 02:48PM]
28-07-2022	PM	8:00 AM ET (Jul 28)	ALNY	Alnylam Pharmaceuticals, Inc.	17,300	-2.29	-1.62	-1.61	Alnylam Pharmaceuticals Non-GAAP EPS of -$2.03 misses by $0.69, revenue of $224.82M misses by $31.24M [7/28/2022 8:10 AM]	143.12	1.16 (0.81%)	137.00	-4.97 (-3.50%)	117.58 - 212.00	458,506	610,000	6,658
Alnylam Pharmaceuticals Q2 2022 Earnings Preview [7/27/2022 1:23 PM] Alnylam to develop cardiometabolic drug after research data on gene mutation [7/27/2022 10:22 AM] Alnylam Pharmaceuticals Non-GAAP EPS of -$2.03 misses by $0.69, revenue of $224.82M misses by $31.24M [7/28/2022 8:10 AM] Alnylam Q2 misses estimates but product revenue soars 33% Y/Y; reaffirms FY22 outlook [7/28/2022 9:50 AM] Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity [Jul-28-22 08:00AM] Drug, Biotech Stocks' Q2 Earnings on Jul 28: MRK, PFE & More [Jul-27-22 02:23PM] Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity [Jul-27-22 08:00AM]
28-04-2022	PM	8:00 AM ET (Apr 28)	ALNY	Alnylam Pharmaceuticals, Inc.	18,710	-2.00	-1.93	-1.71	Alnylam Pharmaceuticals Non-GAAP EPS of -$1.49 misses by $0.03, revenue of $213.26M misses by $29.56M; updates FY22 guidance [4/28/2022 8:04 AM]	143.51	-11.41 (-7.37%)	153.00	-1.92 (-1.24%)	125.00 - 212.00	1,740,796	740,000	3,384
Alnylam Pharmaceuticals Q1 2022 Earnings Preview [4/27/2022 1:46 PM] Alnylam Pharmaceuticals Non-GAAP EPS of -$1.49 misses by $0.03, revenue of $213.26M misses by $29.56M; updates FY22 guidance [4/28/2022 8:04 AM] Alnylam falls 9% after Q1 earnings miss, cut in 2022 net product revenues guidance [4/28/2022 1:20 PM] Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity [Apr-28-22 08:00AM] Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Lags Revenue Estimates [Apr-28-22 09:15AM] How war in Ukraine hit a Vir hepatitis trial: 'Beyond my imagination' [Apr-28-22 05:06PM]
10-02-2022	PM	8:00 AM ET (Feb 10)	ALNY	Alnylam Pharmaceuticals, Inc.	17,660	-2.16	-1.47	-2.09	Alnylam Pharmaceuticals Non-GAAP EPS of -$1.69 misses by $0.43, revenue of $258.54M beats by $24.92M [2/10/2022 8:05 AM]	150.50	-0.90 (-0.59%)	151.70	0.30 (0.20%)	125.00 - 212.00	655,912	790,000	611
Alnylam Pharmaceuticals Q4 2021 Earnings Preview [2/9/2022 12:44 PM] Alnylam Pharmaceuticals Non-GAAP EPS of -$1.69 misses by $0.43, revenue of $258.54M beats by $24.92M [2/10/2022 8:05 AM] Alnylam posts Q4 revenue beat even as annual growth slows [2/10/2022 12:26 PM] Why Alnylam (ALNY) Might Surprise This Earnings Season [Feb-09-22 08:40AM] Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity [Feb-10-22 08:00AM] Alnylam Pharmaceuticals (ALNY) Reports Q4 Loss, Tops Revenue Estimates [Feb-10-22 09:15AM] Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B [Feb-10-22 12:01PM]
28-10-2021	PM	8:00 AM ET (Oct 28)	ALNY	Alnylam Pharmaceuticals, Inc.	23,500	-1.72	-1.51	-2.18	Alnylam Pharmaceuticals EPS misses by $0.27, misses on revenue [10/28/2021 8:03 AM]	162.03	-29.13 (-15.24%)	170.00	-21.16 (-11.07%)	119.29 - 212.00	2,633,973	400,000	16,321
Alnylam vutrisiran benefits patients with hATTR Amyloidosis at 18 months in phase 3 study [10/27/2021 5:42 PM] Alnylam Pharmaceuticals Q3 2021 Earnings Preview [10/27/2021 12:49 PM] Alnylam Pharmaceuticals EPS misses by $0.27, misses on revenue [10/28/2021 8:03 AM] Alnylam Pharmaceuticals announces CEO transition [10/28/2021 8:11 AM] Alnylam falls 18% following Q3 2021 earnings disappointment [10/28/2021 10:29 AM] Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy [Oct-27-21 04:00PM] Alnylam Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity [Oct-28-21 08:00AM] Alnylam Announces Planned CEO Leadership Transition [Oct-28-21 07:55AM] Alnylam CEO to step down at the end of the year [Oct-28-21 11:10AM] Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates [Oct-28-21 09:25AM] Alnylam Stock Dives As Sales Growth Falters And CEO John Maraganore Plans Exit [Oct-28-21 12:25PM] Why Alnylam Pharmaceuticals Is Crashing Today [Oct-28-21 01:48PM] Alnylam's Founding CEO John Maraganore To Exit The Company [Oct-28-21 12:02PM]
03-08-2021	PM	8:00 AM ET (Aug 3)	ALNY	Alnylam Pharmaceuticals, Inc.	21,030	-1.61	-1.57	-1.56	Alnylam Pharmaceuticals EPS misses by $0.05, beats on revenue; Revenue outlook raised [8/3/2021 8:04 AM]	178.68	0.72 (0.40%)	180.03	2.07 (1.16%)	119.29 - 184.83	615,759	560,000	101
Alnylam Pharmaceuticals Q2 2021 Earnings Preview [8/2/2021 12:16 PM] Alnylam Pharmaceuticals EPS misses by $0.05, beats on revenue; Revenue outlook raised [8/3/2021 8:04 AM] Alnylam Pharma lifts 2021 guidance as revenue growth accelerates [8/3/2021 8:39 AM] Drug/Biotech Stock Q2 Earnings on Aug 3: LLY, AMGN & More [Aug-02-21 09:36AM] Alnylam Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Period Activity [Aug-03-21 08:00AM] Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue Estimates [Aug-03-21 09:15AM] Alnylam Pharmaceuticals, inc (ALNY) Q2 2021 Earnings Call Transcript [Aug-03-21 08:00PM]
29-04-2021	PM	8:00 AM ET (Apr 29)	ALNY	Alnylam Pharmaceuticals, Inc.	16,770	-1.71	-1.75	-1.62	Alnylam Pharmaceuticals EPS misses by $0.24, beats on revenue [4/29/2021 8:06 AM]	139.69	-3.84 (-2.68%)	139.69	0.0 (0.00%)	119.29 - 178.41	722,722	480,000	6,430
Alnylam Pharmaceuticals Q1 2021 Earnings Preview [4/28/2021 12:49 PM] Alnylam Pharmaceuticals EPS misses by $0.24, beats on revenue [4/29/2021 8:06 AM] Alnylam posts Q1 results, reiterates financial forecast [4/29/2021 8:34 AM] Alnylam Pharmaceuticals, Inc. to Host Earnings Call [Apr-29-21 06:30AM] Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity [Apr-29-21 08:00AM] Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates [Apr-29-21 09:35AM] Alnylam Pharmaceuticals Inc (ALNY) Q1 2021 Earnings Call Transcript [Apr-29-21 05:01PM]
11-02-2021	PM	8:00 AM ET (Feb 11)	ALNY	Alnylam Pharmaceuticals, Inc.	19,190	-2.09	-1.93	-2.47	Alnylam Pharmaceuticals EPS misses by $0.22, beats on revenue [2/11/2021 8:03 AM]	165.06	0.90 (0.55%)	157.91	-6.25 (-3.81%)	84.97 - 178.41	436,625	796,160	267
Alnylam Pharmaceuticals EPS misses by $0.22, beats on revenue [2/11/2021 8:03 AM] Alnylam Pharmaceuticals Q4 2020 Earnings Preview [2/10/2021 12:19 PM] Alnylam Pharmaceuticals Q4 misses beat, provides 2021 guidance and updates on recent activity [2/11/2021 10:32 AM] Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity [Feb-11-21 08:00AM]
05-11-2020	PM	8:00 AM ET (Nov 5)	ALNY	Alnylam Pharmaceuticals, Inc.	14,970	-2.18	-1.75	-1.92	Alnylam Pharmaceuticals EPS misses by $0.24, beats on revenue [11/5/2020 8:03 AM]	137.86	-1.63 (-1.17%)	137.86	0.0 (0.00%)	84.97 - 167.33	710,674	546,653	27,054

06-08-2020	PM	8:00 AM ET (Aug 6)	ALNY	Alnylam Pharmaceuticals, Inc.	17,490	-1.56	-1.82	-2.02	Alnylam Pharmaceuticals EPS beats by $0.23, beats on revenue [8/6/2020 8:03 AM]	142.98	-7.46 (-4.96%)	150.44	0.0 (0.00%)	69.11 - 167.33	349,696	492,424	56,465

06-05-2020	PM		ALNY	Alnylam Pharmaceuticals, Inc.	15,580	-1.62	-1.89	-1.73	Alnylam Pharmaceuticals EPS misses by $0.01, beats on revenue [5/6/2020 8:03 AM]	141.23	4.60 (3.37%)	141.83	0.60 (0.42%)	65.81 - 147.41	682,019	680,067	242